Epidemiological studies found an increased risk for kidney cancer in hypertensive patients, of which a subgroup has high aldosterone (Ald) levels. We recently showed that Ald is genotoxic both in kidney tubular cells and in rats with mineralocorticoid-mediated hypertension. The present work investigated in vitro and in vivo, if the oxidative stress-mediated activation of the ERK1/2 pathway, and its downstream target STAT3, could be one mechanism involved in the potential oncogenic capability of excess Ald exposure. The effects of excess Ald were investigated in LLC-PK1 cells and in Ald-induced hypertensive rats. Ald caused cRaf, MEK1/2, and ERK1/2 phosphorylation both in LLC-PK1 cells and in rat kidneys. ERK1/2 activation led to an increased phosphorylation of MSK1, p90RSK, and STAT3. The involvement of ERK1/2 in the activation of STAT3 was evidenced by the capacity of the MEK inhibitor U0126 to prevent Ald-mediated ERK1/2 and STAT3 phosphorylation.
| INTRODUCTION
The mineralocorticoid aldosterone (Ald) plays a major role in the maintenance of electrolyte and fluid balance and in regulating blood pressure homeostasis. This is achieved through genomic actions of Ald via the mineralocorticoid receptor (MR). Ald mediates rapid, nongenomic effects, including the activation of NADPH oxidases. 1 On the other hand, we recently showed that excess Ald is genotoxic and causes oxidative stress in renal tubular cells 2, 3 and in rat kidneys. [4] [5] [6] In hypertensive patients, epidemiological studies revealed higher cancer mortality and an increased risk to develop kidney cancer.
Therefore, this cascade participates in the regulation of a large variety of processes, including cell cycle progression, cell survival, cell proliferation, migration, adhesion, differentiation, metabolism, and transcription. 14 It is not surprising that an abnormal activation of the ERK1/2 pathway can lead to cancer. Numerous solid tumors are known to express constitutive levels of phosphorylated ERK1/2, and the ERK1/2 pathway has been validated as target for novel anticancer therapies. 19 The constitutive activation of MEK1/2 has been also shown to result in cellular transformation. 20 A key target of ERK1/2 is the transcription factor signal transducer and activator of transcription 3 (STAT3), which plays major roles in oncogenesis. The STAT proteins are activated by a series of extracellular signaling proteins such as growth factors and hormones, and they are involved in the regulation of physiological processes such as proliferation, apoptosis, and differentiation.
21
STAT3 is phosphorylated at specific serine/threonine residues, which is in part mediated by ERK1/2. 22, 23 Normally, the activation of STAT3 is transient and under tight control, while its aberrant constitutive activation is associated with uncontrolled growth and cancer. 24 In particular, several studies have shown the activation of STAT3 in renal cell carcinomas. [25] [26] [27] Although STATs do not directly regulate cell cycle checkpoints or contribute to the repair of DNA damage, they promote tumorigenesis by deregulating signaling pathways directly involved in those processes. 28 This work investigated both, in vitro and in vivo, the capacity of Ald to activate ERK1/2, and subsequently STAT3. The consequences of ERK/STAT3 activation on two central events in oncogenesis, resistance to apoptosis and increased cell proliferation were studied.
Results show that excess Ald causes the oxidant-mediated activation of ERK1/2/STAT3 in association with abnormal apoptosis/proliferation rates in kidney cells. These findings support the concept that the oncogenic capacity of excess Ald is in part mediated through the activation of the ERK1/2/STAT3 signaling pathways.
| MATERIALS AND METHODS

| Materials
Epithelial porcine kidney cells with proximal tubular properties (LLC- 
| Western blot analysis
Nuclear and total cell fractions were isolated as previously described. 29 To prepare kidney protein extracts, one quarter of each rat kidney was minced under nitrogen, suspended in lysis buffer 
| Determination of mitosis and apoptosis rates
To determine mitotic and apoptotic cells, the protocol for the micronucleus frequency assay was used. 
| TUNEL assay
The frequency of apoptotic cells was detected by the In Situ Cell Death Detection Kit Fluorescein (Roche, Mannheim, Germany) according to the manufacturer's instructions and as described before. 34 Analysis was conducted using an Olympus BX43 microscope with 200-fold magnification. Six visual fields were analyzed per condition with at least 1000 cells per field. The number of TUNEL positive cells was counted and related to the DAPI positive area (as calculated by Image J 1.48r).
| Statistics
To determine significances between the groups SPSS 21 (IBM, Somer) was used, performing one-way analysis of variance (ANOVA) with (Fig. 1A,B) . The phosphorylation of ERK1/2 at Tyr204 in total cell fractions was significantly increased from 2 to 24 h incubation with Ald (Fig. 1C) .
To investigate whether the activated ERK1/2 translocates into the nucleus to phosphorylate nuclear substrates, nuclear fractions of Ald-treated cells were analyzed for ERK1/2, p90RSK, and MSK1 phosphorylation by Western blot. Results showed that ERK1/2 is activated by 10 nM Ald in the nucleus after 1 h incubation, reaching a maximum after 4 h (Fig. 1D ). Ald also caused subsequent phosphorylation of the ERK1/2 downstream nuclear targets p(Ser380)-p90-RSK and p(Thr581)-MSK1
( Fig. 1E,F ).
| Ald activates STAT3
Transcription factor STAT3 is phosphorylated by ERK1/2 at serine 727 (Ser727). To investigate whether Ald activates this transcription factor in LLC-PK1 cells, the STAT3-DNA binding in nuclear fractions was evaluated by EMSA. In LLC-PK1 cells, the activation of STAT3, evaluated as nuclear STAT3-DNA binding by EMSA, was dependent on Ald concentration (5-100 nM). Significance was reached at 10 nM Ald (Fig. 2A) . The maximum of STAT3-DNA binding was reached after 4 h incubation with 10 nM Ald (Fig. 2B) .
A significant increase in STAT3 Ser727 phosphorylation was also observed by Western blot within 1 and 24 h incubation with 10 nM Ald (Fig. 2C) .
| Ald-induced ERK1/2 activation is responsible for STAT3 activation
Given that STAT3 can be also activated by other pathways, the specific activation by ERK1/2 was investigated using an inhibitor of the ERK1/2 signaling pathway. The effects of the MEK1/2 inhibitor U0126 on STAT3 activation was assessed by EMSA and immunostaining. When assessing STAT3 activation, U0126
inhibited Ald-mediated increase in STAT3-DNA binding (EMSA) (Fig. 3A) . Furthermore, immunofluorescence staining revealed that after 4 and 24 h of treatment with 10 nM Ald, p-STAT3 nuclear abundance was significantly increased by Ald, which was prevented by simultaneously treating the cells with U0126 ( To investigate if the Ald-triggered activation of ERK1/2 and STAT3 is mediated via the MR, the effects of the MR antagonist eplerenone were assessed. Ald-mediated ERK1/2 activation and the subsequent activation of STAT3 were both significantly reduced by eplerenone (Fig. 4A,B) . To investigate the hypothesis that ERK1/2 activation and the subsequent activation of STAT3 occurred as a consequence of increased cellular oxidants, the influence of the cell permeant antioxidant tempol was investigated. Ald-induced activation of ERK1/2 and STAT3 was prevented by the simultaneous incubation of LLC-PK1 cells with tempol (Fig. 4C,D) . These findings suggested that Ald-induced ERK1/2 activation and subsequent activation of STAT3 occurs through an increase in the inhibitor L-NAME. VAS and L-NAME caused a significant inhibition of ERK1/2 and STAT3 activation as determined by Western blot and EMSA, respectively (Fig. 4C,D) . (Fig. 5A,B) .
Consistently, at 24 h of treatment, U0126 significantly reduced cell growth by 55% as determined using the CellTiter-Glo Luminiscent Cell Viability Assay. Although Ald did not affect cell viability, it acted attenuating the decrease in cell viability caused by U0126 (Fig. 5C ). We next investigated the expression of PCNA, a protein which is found in the cell nucleus during the S-phase of the cell cycle. In agreement with the raised cell proliferation of Ald-treated cells, PCNA protein levels measured by Western blot were significantly increased in Ald-treated cells within 0.5 and 24 h of incubation (Fig. 5D ).
| Ald-mediated activation of ERK1/2 leads to reduced apoptosis
Besides an enhanced cell proliferation, resistance to apoptosis plays an important role in the development of cancer. For this purpose, we evaluated, by Annexin V staining, the effect of Ald on phosphati- (Fig. 6A,B) . with Ald and U0126 not only prevented the reduction caused by Ald, but led to a two-to threefold increase in apoptotic rates (Fig. 6C,D) .
Moreover, Western blots for the anti-apoptotic protein Bcl XL and the pro-apoptotic proteins Bcl XS and Bak were done in Ald-treated LLC-PK1 cells. A significant increase of the anti-apoptotic protein Bcl xL was observed after 0.5, 2, 4, and 24 h incubation with 10 nM Ald (Fig. 6E) , whereas a significant decrease of the pro-apoptotic proteins Bcl xs and Bak was observed in Ald-treated cells after 4 and 24 h or 2-24 h, respectively (Fig. 6E ).
| In vivo experiments 4.2.1 | Ald activates the ERK1/2 signaling pathway
To investigate if hyperaldosteronism also causes activation of the ERK1/2 signaling pathway in vivo, IHC analysis for p-ERK1/2 (Tyr204) was done in kidney cortex. A significant increase of p-ERK1/2-positive nuclei was found in renal cortex and medulla from Ald-treated rats, which was prevented/ mitigated when simultaneously treated with spironolactone, apocynin and L-NAME (Fig. 7A,B) . A similar pattern of effects on ERK1/2 phosphorylation was observed by Western blot in total kidney extracts (Fig. 7C) .
The upstream MEK1/2 is located in the cytoplasm. IHC staining showed a significant increase of phospho-MEK1/2-positive tubules in the cortex and a significant reduction of the staining in the apocynin/Ald and L-NAME/Ald groups (Fig. 8A,B) . In the medulla the increase in MEK phosphorylation, although almost double that of the controls, was not statistically significant (Fig. 8B) . Downstream of ERK1/2, MSK1 and 90RSK phosphorylation was assessed. pMSK1-positive nuclei were significantly higher in the renal cortex and medulla from the Ald-treated group compared to controls (Fig. 8A,C) . A significant reduction of pMSK1-positive nuclei was observed in the apocynin/Ald group in cortex and medulla and in medulla from the L-NAME/Ald group (Fig. 8C) . p-p90RSK-positive nuclei were more than three times higher in cortex and medulla in Ald-treated rat kidneys compared to controls, and a significant reduction of p-p90RSK-positive nuclei was found in the whole kidney from rats simultaneously treated with spironolactone, apocynin and L-NAME (Fig. 8D) . Representative pictures are depicted in Fig. 8A .
| Ald activates STAT3 in vivo
The in vivo Ald-mediated phosphorylation of STAT3 at Ser727 was next investigated. IHC staining showed a significant increase of p-STAT3-positive nuclei in cortex and medulla of Ald-treated animals compared to controls, while a significant reduction of p-STAT3-positive nuclei was found in the rats treated simultaneously with spironolactone, apocynin and L-NAME in the cortex, but only with apocynin in the medulla (Fig. 8A,E) .
| Ald-mediated ERK1/2/STAT3 activation modulates cell proliferation and apoptosis in vivo
In vivo cell proliferation was investigated by IHC for PCNA, a protein critical for DNA replication. A significant increase of PCNA-positive nuclei was observed in the renal cortex and | 1877 medulla from Ald-treated rats compared to controls. PCNApositive nuclei were significantly lower in kidneys from rats treated simultaneously with Ald and spironolactone, apocynin or L-NAME (Fig. 9A,B) . Staining for apoptosis with the TUNEL assay did not show significant differences in the kidney (Fig. 9C) . In the cortex, the amount of apoptotic cells of Ald-treated animals showed a trend (P = 0.08) for higher values than in controls. Spironolactone significantly reduced apoptosis in the cortex compared to Ald-treated animals and in the medulla compared to control animals.
The expression of the anti-apoptotic protein Bcl XL was significantly increased in total kidney extracts of the Ald-treated group whereas that of the pro-apoptotic protein Bcl XS was significantly decreased. No statistical differences were observed among Spironolactone-, apocynin-, and L-NAME-treated groups (Fig. 9D,E) .
| DISCUSSION
This paper investigated if the Ras/Raf/MEK/ERK pathway and its downstream target, the STAT3 transcription factor, could contribute to kidney cell survival and proliferation when exposed to excess Ald.
We found that both in vitro and in vivo, Ald promoted the activation of Ras/Raf/MEK/ERK and of STAT3, which was associated with increased cell mitosis and decreased apoptosis, central events in cancer promotion and development. In vivo and in vitro studies point to a major role of NADPH oxidase and NO synthase activation in the triggering of these oncogenic events by excess Ald.
Activation of the Ras/Raf/MEK/ERK pathway has key regulatory functions on cell proliferation, apoptosis and differentiation. ERK1/2 aberrant activation is associated with increased cell growth and oncogenesis. 35 As we currently observed for Ald in LLC-PK1 cells and rat kidney tubules, the MR-dependent activation of Raf, MEK1/2 and ERK1/2 was previously reported in smooth muscle cells, cardiac fibroblasts and kidney cells. [36] [37] [38] [39] Once activated, ERK1/2 primarily phosphorylates a large number of target substrates on serine or threonine residues followed by a proline residue. 40 Given in LLC-PK1 cells and in the rat renal cortex. Ald/NAD(P)H oxidasemediated activation of ERK, and consequently of STAT3, can occur through several mechanisms including: i) the oxidation-dependent inhibition of intracellular tyrosine phosphatases; and ii) oxidantsmediated expression and activation of the small Rac protein upstream of ERK. 53 In fact, the NAD(P)H oxidase-dependent activation of STAT3 by angiotensin II was described in rat aortic smooth muscle cells. 54 The link among NO synthase activation, increased NO production, ERK1/2 activation, and cancer has been previously described. For example, pretreatment of human astrocytoma cells with the NO synthase inhibitor L-NAME antagonized ERK1/2 leading to reduced cell proliferation. 55 In line with these findings, we currently observed both in vitro and in vivo, that L-NAME significantly reduced
Ald-induced ERK1/2 activation in kidney cells.
In agreement with our previous findings 5 and with the roles of ERK1/2 and STAT3 on cell proliferation and survival, Ald caused an increase in cell proliferation both in vitro and in vivo. Increased cell proliferation was previously detected in kidneys from DOCA/salttreated rats, mainly in the tubular regions. 56 Enhanced cell proliferation is also found in the brain from DOCA/salt-treated rats. | 1881 the concept that Ald might indeed play a so far undescribed but important role in the increased kidney cancer risk observed in hypertensive patients.
